Dynavax raises $44M in offering; Which drugs will be pharma's top 2014 blockbusters?;

 @FierceBiotech: Biotechs cater to the most creative scientists. Article | Follow @FierceBiotech

 @JohnCFierce: Hey, stock watchers. What's up with Rexahn shares, up 27% this morning? Corporate update scheduled for tomorrow. Story | Follow @JohnCFierce

> Roche AG has acquired insulin pump developer Medingo from Elron Electronic Industries and its partners for $160 million as well as up to $40 million in milestone payments. Report

> ChemGenex Pharmaceuticals announced that the FDA's Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO (omacetaxine mepesuccinate) for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation. ChemGenex release

> Intercept Pharmaceuticals today announced the presentation of the results from its recently completed Phase II clinical trial of INT-747 (obeticholic acid) in patients with primary biliary cirrhosis. Intercept elease

> Dynavax Technologies today announced the pricing of an underwritten offering resulting in gross proceeds of $44 million, before deducting estimated offering expenses. Dynavax release

And Finally... Which drugs will be pharma's top 2014 blockbusters? Answer

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.